Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | RAF1 | P04049 | 2/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6189877 | 1.00 | INSR (0.35) | INSRALKALDH1A1RAF1ADRA1D | |
| SCHEMBL4808356 | 0.92 | INSR (0.35) | INSRALKALDH1A1HRH3SMN1; SMN2 | |
| SCHEMBL4808351 | 0.92 | INSR (0.35) | INSRALKALDH1A1HRH3SMN1; SMN2 | |
| SCHEMBL6193876 | 0.92 | POLB (0.39) | INSRALKALDH1A1ADRA1DADRA1A | |
| SCHEMBL6193870 | 0.92 | POLB (0.39) | INSRALKALDH1A1ADRA1DADRA1A | |
| SCHEMBL4700317 | 0.90 | INSR (0.38) | INSRALKALDH1A1RAF1HRH3 | |
| SCHEMBL4700319 | 0.90 | INSR (0.38) | INSRALKALDH1A1RAF1HRH3 | |
| SCHEMBL4703440 | 0.90 | INSR (0.36) | INSRALKALDH1A1RAF1HRH3 | |
| SCHEMBL4703439 | 0.90 | INSR (0.36) | INSRALKALDH1A1RAF1HRH3 | |
| SCHEMBL6195591 | 0.89 | INSR (0.37) | INSRALKALDH1A1HRH3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1345892-B1 | ACYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES | AVENTIS PHARMA GMBH (DE) | 2005-03-09 | — | — | EP | disclosed |
| EP-1345892-A2 | ACYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES | Aventis Pharma Deutschland GmbH (DE) | 2003-09-24 | — | — | EP | disclosed |
| US-6511989-B2 | For therapy of vagal dysfunction in the heart, improving cardiac function, therapy of person susceptible to cardiac death | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-01-28 | — | — | US | disclosed |
| US-20020123494-A1 | Acylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-05 | — | — | US | disclosed |
| WO-2002036556-A2 | ACYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123494-A1 | Acylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them | KCNJ11, KCNJ1, KCNA1 | INSR 945/4885ALK 498/4885ALDH1A1 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.